A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 17, 2026 - P2 | N=36 | Not yet recruiting | Sponsor: Fudan University
dMMR • Mismatch repair • MSI-H • New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Microsatellite Instability • Oncology • Solid Tumor • MLH1 • MSH2 • MSH6 • MSI
|